evaluation of the effectiveness and safety of dospray® nazal spray in the symptomatic treatment of persistent allergic rhinitis: a post-registration observation study

Conditions: Allergic Rhinitis

Summary: the combined use of dexamethasone and oxymetazoline has a vasoconstrictive, anti-inflammatory and anti-allergic effect when applied topically in diseases of the upper respiratory tract. the main goal of this research is evaluation of the effectiveness of dospray® nasal spray in the treatment of persistent allergic rhinitis. the study will involve 126 patients diagnosed with allergic rhinitis: 1. patients taking dospray = 63 2. patients on other alternative treatment = 63 duration of patient participation - 7-10 days (duration of treatment for an individual patient).

primary task: overall assessment of the effectiveness of dospray® nasal spray in the treatment of persistent allergic rhinitis. secondary tasks: * symptomatic evaluation of the effectiveness of dospray® nasal spray in the treatment of persistent allergic rhinitis; * evaluation of the effect of dospray® nasal spray on conjunctive symptoms in the treatment of persistent allergic rhinitis; * evaluation of the effect of dospray® nasal spray on the severity and frequency of nasal symptoms in the treatment of persistent allergic rhinitis; * assessment of the quality of life before and after the use of dospray® nasal spray in the treatment of persistent allergic rhinitis; * safety assessment of the use of nasal spray dospray®. study endpoints: 1. dynamics of scores on the scale of the reflective total nasal symptoms score (tnss) \[time: 7 days\] 2. dynamics of scores on the scale of the individual reflective total nasal symptoms score (itnss) \[time: 7 days\] 3. dynamics of scores on the scale of the reflective total ocular symptom score (rtoss) 4. changes in visual analogue scale (vas) scores for the severity and frequency of nasal symptoms \[time: 7 days\]. 5. dynamics of scores on the rhinoconjunctivitis quality of life questionnaire (rqlq) scores \[time: 7 days\] 6. adverse reactions \[time: 7 days\] number of yellow cards.

Eligibility criteria:
inclusion criteria: * persons aged 18 to 65 years * total tnss score on the day of inclusion in the study equal to or greater than 4. * patients who were prescribed the drug dospray® or other symptomatic treatment as part of routine medical practice outside the study. * voluntary desire to provide informed consent to participate in the study. exclusion criteria: * objective symptoms suggestive of renal, hepatic, or heart failure; * pregnant and lactating women; * patients taking systemic steroids within 30 days prior to inclusion in the study; * use of nasal sprays containing corticosteroids within 30 days prior to enrollment in the study; * patients receiving immunomodulatory therapy (including allergen specific immunotherapy (asit)); * patients taking drugs for the treatment of bronchial asthma; * patients with polyps in the nasal cavity and / or deformity of the nasal septum requiring surgical correction; * infectious diseases of the upper respiratory tract within 14 days before enrollment in the study; * patients prone to nosebleeds, having glaucoma, convulsive syndrome or other neuropsychiatric pathologies.